Research
Print page Print page
Switch language
The Capital Region of Denmark - a part of Copenhagen University Hospital

Christina Friese

Herlev Hospital, Herlev Ringvej 75

Building: 81-05-PV9

2730 Herlev

Denmark

  1. 2020
  2. Published

    CTLA-4 blockade boosts the expansion of tumor-reactive CD8+ tumor-infiltrating lymphocytes in ovarian cancer

    Friese, C., Harbst, K., Borch, T. H., Westergaard, M. C. W., Pedersen, M., Kverneland, A., Jönsson, G., Donia, M., Svane, I. M. & Met, Ö., 3 Mar 2020, In: Scientific Reports. 10, 1, p. 3914 3914.

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Published
  4. 2019
  5. Published

    Inflammation induced PD-L1-specific T cells

    Munir, S., Lundsager, M. T., Jørgensen, M. A., Hansen, M., Petersen, T. H., Bonefeld, C. M., Friese, C., Met, Ö., Straten, P. T. & Andersen, M. H., 13 Sep 2019, In: Cell stress. 3, 10, p. 319-327 9 p.

    Research output: Contribution to journalJournal articleResearchpeer-review

  6. Published
  7. Published

    Tumour-reactive T cell subsets in the microenvironment of ovarian cancer

    Westergaard, M. C. W., Andersen, R., Chong, C., Kjeldsen, J. W., Pedersen, M., Friese, C., Hasselager, T., Lajer, H., Coukos, G., Bassani-Sternberg, M., Donia, M. & Svane, I. M., 19 Feb 2019, In: British Journal of Cancer. 120, 4, p. 424-434 11 p.

    Research output: Contribution to journalJournal articleResearchpeer-review

  8. 2018
  9. Published

    SATB1 in Malignant T Cells

    Fredholm, S., Willerslev-Olsen, A., Met, Ö., Kubat, L., Gluud, M., Mathiasen, S. L., Friese, C., Blümel, E., Petersen, D. L., Hu, T., Nastasi, C., Lindahl, L. M., Buus, T. B., Krejsgaard, T., Wasik, M. A., Kopp, K. L., Koralov, S. B., Persson, J. L., Bonefeld, C. M., Geisler, C., Woetmann, A., Iversen, L., Becker, J. C. & Ødum, N., Aug 2018, In: The Journal of investigative dermatology. 138, 8, p. 1805-1815 11 p.

    Research output: Contribution to journalJournal articleResearchpeer-review

  10. Published

    The calreticulin (CALR) exon 9 mutations are promising targets for cancer immune therapy

    Holmström, M. O., Martinenaite, E., Ahmad, S. M., Met, Ö., Friese, C., Kjær, L., Riley, C. H., Thor Straten, P., Svane, I. M., Hasselbalch, H. C. & Andersen, M. H., 2018, In: Leukemia. 32, 2, p. 429-437 8 p.

    Research output: Contribution to journalJournal articleResearchpeer-review

ID: 52220947